All lobbying filings

AVENUE SOLUTIONS

AVENUE SOLUTIONS filed a Q3 report for MERCK & CO. INC. on October 20, 2026, reporting $50,000 in lobbying income.

Lobbying for MERCK & CO. INC. · developer, manufacturer and distributor of pharmaceuticals

All filings by AVENUE SOLUTIONS · Everything MERCK & CO. INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to vaccines; Issues related to 340b

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act

Bills named in this filing 1

H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.